These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 21547501)

  • 1. How tumors might withstand γδ T-cell attack.
    Capietto AH; Martinet L; Fournié JJ
    Cell Mol Life Sci; 2011 Jul; 68(14):2433-42. PubMed ID: 21547501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pitfalls on the roadmap to gammadelta T cell-based cancer immunotherapies.
    Martinet L; Poupot R; Fournié JJ
    Immunol Lett; 2009 May; 124(1):1-8. PubMed ID: 19465238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. γδ T cells in cancer immunotherapy.
    Zou C; Zhao P; Xiao Z; Han X; Fu F; Fu L
    Oncotarget; 2017 Jan; 8(5):8900-8909. PubMed ID: 27823972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BTN3A1-antibodies and phosphoantigens: TCRVγ9Vδ2 "see" the difference.
    Franchini DM; Michelas M; Lanvin O; Poupot M; Fournié JJ
    Eur J Immunol; 2017 Jun; 47(6):954-957. PubMed ID: 28597565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The subtle interplay between gamma delta T lymphocytes and dendritic cells: is there a role for a therapeutic cancer vaccine in the era of combinatorial strategies?
    Galati D; Zanotta S; Bocchino M; De Filippi R; Pinto A
    Cancer Immunol Immunother; 2021 Jul; 70(7):1797-1809. PubMed ID: 33386466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. γδ T-APCs: a novel tool for immunotherapy?
    Moser B; Eberl M
    Cell Mol Life Sci; 2011 Jul; 68(14):2443-52. PubMed ID: 21573785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors.
    Noguchi A; Kaneko T; Kamigaki T; Fujimoto K; Ozawa M; Saito M; Ariyoshi N; Goto S
    Cytotherapy; 2011 Jan; 13(1):92-7. PubMed ID: 20831354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vγ9Vδ2 T cell-based immunotherapy in hematological malignancies: from bench to bedside.
    Castella B; Vitale C; Coscia M; Massaia M
    Cell Mol Life Sci; 2011 Jul; 68(14):2419-32. PubMed ID: 21584812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. γδ cells and tumor microenvironment: A helpful or a dangerous liason?
    Lo Presti E; Di Mitri R; Pizzolato G; Mocciaro F; Dieli F; Meraviglia S
    J Leukoc Biol; 2018 Mar; 103(3):485-492. PubMed ID: 29345336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human γδ T-cell responses in infection and immunotherapy: common mechanisms, common mediators?
    Riganti C; Massaia M; Davey MS; Eberl M
    Eur J Immunol; 2012 Jul; 42(7):1668-76. PubMed ID: 22806069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies to Improve the Antitumor Effect of γδ T Cell Immunotherapy for Clinical Application.
    Miyashita M; Shimizu T; Ashihara E; Ukimura O
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What lessons can be learned from γδ T cell-based cancer immunotherapy trials?
    Fournié JJ; Sicard H; Poupot M; Bezombes C; Blanc A; Romagné F; Ysebaert L; Laurent G
    Cell Mol Immunol; 2013 Jan; 10(1):35-41. PubMed ID: 23241899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. γδ T-cell immunotherapy for lung cancer.
    Yoshida Y; Nakajima J; Wada H; Kakimi K
    Surg Today; 2011 May; 41(5):606-11. PubMed ID: 21533930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal Cell Carcinoma-Infiltrating CD3
    Lee HW; Park C; Joung JG; Kang M; Chung YS; Oh WJ; Yeom SY; Park WY; Kim TJ; Seo SI
    Curr Issues Mol Biol; 2021 May; 43(1):226-239. PubMed ID: 34071865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression.
    Stolk D; van der Vliet HJ; de Gruijl TD; van Kooyk Y; Exley MA
    Front Immunol; 2018; 9():1990. PubMed ID: 30298063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aminobisphosphonates as new weapons for gammadelta T Cell-based immunotherapy of cancer.
    Caccamo N; Meraviglia S; Cicero G; Gulotta G; Moschella F; Cordova A; Gulotta E; Salerno A; Dieli F
    Curr Med Chem; 2008; 15(12):1147-53. PubMed ID: 18473809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-peptide antigens activating human Vgamma9/Vdelta2 T lymphocytes.
    Poupot M; Fournié JJ
    Immunol Lett; 2004 Sep; 95(2):129-38. PubMed ID: 15388252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies.
    Deniger DC; Maiti SN; Mi T; Switzer KC; Ramachandran V; Hurton LV; Ang S; Olivares S; Rabinovich BA; Huls MH; Lee DA; Bast RC; Champlin RE; Cooper LJ
    Clin Cancer Res; 2014 Nov; 20(22):5708-19. PubMed ID: 24833662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. γδ T cells and their potential for immunotherapy.
    Wu YL; Ding YP; Tanaka Y; Shen LW; Wei CH; Minato N; Zhang W
    Int J Biol Sci; 2014; 10(2):119-35. PubMed ID: 24520210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Function of γδ T cells in tumor immunology and their application to cancer therapy.
    Park JH; Lee HK
    Exp Mol Med; 2021 Mar; 53(3):318-327. PubMed ID: 33707742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.